Welcome to our dedicated page for Biocryst Pharmaceuticals SEC filings (Ticker: BCRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioCryst Pharmaceuticals, Inc. SEC filings document the company's commercial rare-disease business, including ORLADEYO® results, revenue guidance, pricing disclosures, and financial results furnished on Form 8-K. The filings also describe pipeline and business-development matters involving HAE programs, including navenibart licensing and the completed acquisition of Astria Therapeutics as a BioCryst subsidiary.
BioCryst's filings further cover financing and capital-structure matters, including term-loan arrangements, as well as proxy disclosures on board elections, executive compensation, equity awards, committee structure, and shareholder voting matters. Material-event reports and proxy statements provide the formal record for governance changes, strategic transactions, and Regulation FD disclosures.
BioCryst Pharmaceuticals completed its acquisition of Astria Therapeutics for total consideration of $874.3M, mainly to obtain the navenibart rare-disease program. The company expensed $697.8M of acquired in-process R&D, driving a quarterly net loss of $721.8M despite revenue of $156.4M, including $148.3M from ORLADEYO. To help fund the cash portion of the deal, BioCryst drew a $400M secured term loan from Blackstone, contributing to total royalty financing obligations and debt of roughly $842.7M. Cash, cash equivalents and restricted cash were $173.4M, while accumulated losses widened and stockholders’ deficit increased to $553.8M.
BioCryst Pharmaceuticals reported first quarter 2026 results with strong growth in its core hereditary angioedema franchise but a large accounting loss from an acquisition. ORLADEYO net revenue reached $148.3 million, up 11% year over year, helping drive total revenue of $156.4 million.
The company recorded a GAAP operating loss of $701.6 million, mainly due to a special, non-cash $697.8 million charge for acquired in-process R&D from its Astria Therapeutics acquisition. On a non-GAAP basis, it generated an operating profit of $54.2 million. Cash, cash equivalents, restricted cash and investments totaled $260.8 million at March 31, 2026, or $330.8 million on a pro forma basis including $70 million received after quarter end from licensing European rights to navenibart.
BioCryst entered a European navenibart license with an Irish affiliate of Neopharmed Gentili, adding up to $275 million in potential milestones and tiered royalties of 18%–30%. It reaffirmed 2026 guidance for global ORLADEYO net revenue of $625–$645 million, total revenue of $635–$660 million, and non-GAAP operating expenses of $450–$470 million, while advancing the navenibart pivotal trial and a Phase 1 study of BCX17725.
BioCryst Pharmaceuticals entered a European license agreement granting an Irish affiliate of Neopharmed Gentili exclusive rights to commercialize navenibart for hereditary angioedema. BioCryst will receive $70 million upfront, up to $275 million in future regulatory and sales milestone payments, plus tiered royalties on net sales ranging from 18% to 30%.
Navenibart is an investigational, long-acting plasma kallikrein inhibitor currently in a Phase 3 program in hereditary angioedema, with the program described as on track to support a US regulatory filing by the end of 2027. The company highlights that the deal strengthens its financial position while leveraging Neopharmed Gentili’s existing European rare disease infrastructure.
BioCryst Pharmaceuticals Inc reports that Vanguard Capital Management beneficially owns 12,961,172 shares of Common Stock as of 03/31/2026, representing 5.16% of the class.
The filing lists sole voting power of 1,825,410 shares and sole dispositive power over 12,961,172 shares. The Schedule 13G was signed by Ashley Grim on 04/29/2026.
BioCryst Pharmaceuticals is holding its 2026 annual stockholder meeting on June 11, 2026 to vote on key governance and compensation matters. Stockholders will elect three directors for terms ending in 2029, ratify Ernst & Young LLP as auditor for 2026, and cast an advisory vote on executive pay.
A major proposal seeks approval of an amended and restated Stock Incentive Plan adding 7,000,000 shares. As of April 13, 2026, 54,027,003 shares were reserved or available under the plan, with 254,105,895 common shares outstanding, implying potential dilution of 2.8%. The company argues the increase is needed to attract and retain talent, support ORLADEYO commercialization and pipeline programs, and maintain a broad-based equity culture. The plan includes shareholder-friendly terms such as no repricing without approval, a minimum one-year vesting rule (with limited exceptions), caps on director compensation, no evergreen feature, and double-trigger change-of-control vesting.
BioCryst Pharmaceuticals Chief R&D Officer Sandeep Menon received equity grants as part of his compensation. On April 6, 2026, he was granted 441,350 employee stock options for common stock at an exercise price of $9.47 per share, expiring in 2036.
He also received an inducement grant of 205,150 restricted stock units of common stock. Both the RSUs and the options vest or become exercisable in equal 25% installments on each of the first, second, third and fourth anniversaries of the grant date, aligning his incentives with longer-term company performance rather than reflecting open-market trading.
BIOCRYST PHARMACEUTICALS INC filed an initial Form 3 for Chief R&D Officer Sandeep Menon. This document establishes his status as a reporting insider at the company. The filing does not list any transactions, so it serves mainly as a baseline disclosure of his insider reporting obligations.
BioCryst Pharmaceuticals disclosure: The Vanguard Group filed an amendment to its Schedule 13G reporting 0 shares beneficially owned, representing 0% of Common Stock as of the amendment. The filing explains an internal realignment that disaggregated certain Vanguard subsidiaries' reporting of holdings.
BIOCRYST PHARMACEUTICALS INC director Theresa Heggie exercised stock options and sold shares on March 20, 2026. She exercised options for 49,933 shares of Common Stock at an exercise price of $6.30 per share and acquired the same number of shares.
She then sold 49,933 Common shares in an open-market transaction at a weighted average price of $10.11 per share, in multiple trades between $10.09 and $10.14. Following these transactions, she directly holds 65,352 shares of Common Stock.